Cargando…

Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations

The object of this study was to prepare binary and ternary solid dispersions of atorvastatin (ATR) by the melting method using PEGs and poloxamer 188 (P188) as the carriers, singly and in combination with each other. Dissolution behavior, solubility studies, X-ray diffractometry, differential scanni...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraji, Elahe, Mohammadi, Mojdeh, Mahboobian, Mohammad Mehdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437629/
https://www.ncbi.nlm.nih.gov/pubmed/34527740
http://dx.doi.org/10.1155/2021/6644630
_version_ 1783752191817809920
author Faraji, Elahe
Mohammadi, Mojdeh
Mahboobian, Mohammad Mehdi
author_facet Faraji, Elahe
Mohammadi, Mojdeh
Mahboobian, Mohammad Mehdi
author_sort Faraji, Elahe
collection PubMed
description The object of this study was to prepare binary and ternary solid dispersions of atorvastatin (ATR) by the melting method using PEGs and poloxamer 188 (P188) as the carriers, singly and in combination with each other. Dissolution behavior, solubility studies, X-ray diffractometry, differential scanning calorimetry, and Fourier transform infrared spectroscopy were studied. Furthermore, antihyperlipidemic activities of formulations were compared to each other by serum lipid analyses in hyperlipidemic rats. Based on the results, the highest dissolution efficiency (DE30 = 83%) was obtained by binary systems consisted of ATR and P188. Also, no additional improvement was observed in dissolution properties of ternary solid dispersion formulations. Solubility studies showed enhancement of ATR phase solubility in water and a buffer solution containing P188 or PEG 10000. Furthermore, saturated solubility of ATR in the buffer solution improved more than twofold in the optimized ternary dispersion system. No crystalline changes occurred in PEG-based formulations; meanwhile, partial amorphization happened in the ATR-P188 combination. Finally, the in vivo study in hyperlipidemic rats exhibited a rapid decrease in the lipid profile of all formulations compared to ATR (after 7 days). Moreover, reduction of serum triglycerides and total cholesterol on the 14th day in the ATR group (p value < 0.01) was less than solid dispersion or physical mixing preparations (p value < 0.001). These findings proved the appropriate influence of using PEG and P188 in solid dispersion systems for the improvement of the therapeutic efficiency of ATR.
format Online
Article
Text
id pubmed-8437629
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-84376292021-09-14 Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations Faraji, Elahe Mohammadi, Mojdeh Mahboobian, Mohammad Mehdi Biomed Res Int Research Article The object of this study was to prepare binary and ternary solid dispersions of atorvastatin (ATR) by the melting method using PEGs and poloxamer 188 (P188) as the carriers, singly and in combination with each other. Dissolution behavior, solubility studies, X-ray diffractometry, differential scanning calorimetry, and Fourier transform infrared spectroscopy were studied. Furthermore, antihyperlipidemic activities of formulations were compared to each other by serum lipid analyses in hyperlipidemic rats. Based on the results, the highest dissolution efficiency (DE30 = 83%) was obtained by binary systems consisted of ATR and P188. Also, no additional improvement was observed in dissolution properties of ternary solid dispersion formulations. Solubility studies showed enhancement of ATR phase solubility in water and a buffer solution containing P188 or PEG 10000. Furthermore, saturated solubility of ATR in the buffer solution improved more than twofold in the optimized ternary dispersion system. No crystalline changes occurred in PEG-based formulations; meanwhile, partial amorphization happened in the ATR-P188 combination. Finally, the in vivo study in hyperlipidemic rats exhibited a rapid decrease in the lipid profile of all formulations compared to ATR (after 7 days). Moreover, reduction of serum triglycerides and total cholesterol on the 14th day in the ATR group (p value < 0.01) was less than solid dispersion or physical mixing preparations (p value < 0.001). These findings proved the appropriate influence of using PEG and P188 in solid dispersion systems for the improvement of the therapeutic efficiency of ATR. Hindawi 2021-09-04 /pmc/articles/PMC8437629/ /pubmed/34527740 http://dx.doi.org/10.1155/2021/6644630 Text en Copyright © 2021 Elahe Faraji et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Faraji, Elahe
Mohammadi, Mojdeh
Mahboobian, Mohammad Mehdi
Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title_full Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title_fullStr Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title_full_unstemmed Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title_short Development of the Binary and Ternary Atorvastatin Solid Dispersions: In Vitro and In Vivo Investigations
title_sort development of the binary and ternary atorvastatin solid dispersions: in vitro and in vivo investigations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437629/
https://www.ncbi.nlm.nih.gov/pubmed/34527740
http://dx.doi.org/10.1155/2021/6644630
work_keys_str_mv AT farajielahe developmentofthebinaryandternaryatorvastatinsoliddispersionsinvitroandinvivoinvestigations
AT mohammadimojdeh developmentofthebinaryandternaryatorvastatinsoliddispersionsinvitroandinvivoinvestigations
AT mahboobianmohammadmehdi developmentofthebinaryandternaryatorvastatinsoliddispersionsinvitroandinvivoinvestigations